Anavex/$AVXL

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Anavex

Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are further used in the analysis of clinical trials. The company's focus is on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its various therapeutic candidates in different stages of development include Anavex 2-73 (Blacamesine), Anavex 3-71 (AF710B), Anavex 1-41, and Anavex 1066.

Ticker

$AVXL
Sector
Primary listing

Employees

42

Anavex Metrics

BasicAdvanced
$805M
-
-$0.57
0.80
-

What the Analysts think about Anavex

Analyst ratings (Buy, Hold, Sell) for Anavex stock.

Bulls say / Bears say

Anavex completed full enrollment of its Phase 2 ANAVEX®3-71 schizophrenia trial with 71 participants on May 1, 2025, laying groundwork for top-line data expected in the second half of 2025 (GlobeNewswire).
Open-label extension data from the Phase IIb/III ATTENTION-AD OLE trial demonstrated sustained, clinically meaningful benefits through three years of continuous blarcamesine treatment in early Alzheimer’s patients (TradingView/GlobeNewswire).
Robust liquidity with $101.2 million in cash and equivalents as of June 30, 2025, provides an approximate cash runway of more than three years (GlobeNewswire).
Cash reserves declined by over $31 million from $132.2 million at September 30, 2024 to $101.2 million at June 30, 2025, reflecting a burn rate that pressures future financing needs (GlobeNewswire).
General and administrative expenses surged to $4.5 million in Q3 FY25, up from $2.8 million a year earlier, pointing to escalating overhead costs (GlobeNewswire).
Third-quarter net loss widened to $13.2 million (−$0.16 per share) from $12.2 million (−$0.14) YoY, underscoring mounting losses as development programs advance (GlobeNewswire).
Data summarised monthly by Lightyear AI. Last updated on 5 Sept 2025.

Anavex Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Anavex Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $AVXL

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs